Amish C. Shah, MD, PhD
Amish C. Shah, MD, PhD

Amish C. Shah, MD, PhD

Amish C. Shah, MD, PhD, is a neuro-oncologist and Director of the Neuro-Oncology Fellowship Program at Children's Hospital of Philadelphia.

Areas of expertise: Pediatric brain and spine tumors, Neurofibromatosis type 1, Neurofibromatosis type 2, Neurofibromatosis-related malignancies, Retinoblastoma, Ocular/eye tumors, Histiocytic tumors primarily in the CNS (Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, etc.)

Locations: Main Building


215-590-3025

267-426-0762

About Amish C. Shah, MD, PhD

Titles

Attending Physician

Assistant Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

Awards and Honors

2012-2014, T32, Grant: 5T32CA009615-23, PI: John Maris; Post-doctoral appointment
2004-2007, Ruth L. Kirschstein National Research Service Award, NIH: 1 F31 NS050924-01
2006, Oral Presentation Research Award, International Herpesvirus Workshop, Seattle, WA
2005, AAAS Science Award
2004, Outstanding Cancer Research, Medical Student Research, UASOM
1999, Graduated Summa Cum Laude - University of Georgia, Athens, GA

Education & training

Medical Degree

MD/PhD, Medical Scientist Training Program - University of Alabama School of Medicine, Birmingham, AL

Residency

Pediatrics (Integrated Research Pathway) - The Children’s Hospital of Philadelphia, Philadelphia, PA

Fellowship

Pediatric Neuro-Oncology - The Children’s Hospital of Philadelphia, Philadelphia, PA
Pediatric Oncology/Hematology - The Children’s Hospital of Philadelphia, Philadelphia, PA

Team affiliations

 View fewer all team affiliations View all all team affiliations

Publications

Publications

2020

Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick MC, Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina O, Heisey K, Clapp DW, Zhang C, Peer CJ, Figg WD, Smith M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LA, Widemann BC. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med. 2020 Apr 9;382(15):1430-1442. doi: 10.1056/NEJMoa1912735. Epub 2020 Mar 18. PMID: 32187457

2019

Vogel J, Grewal A, O'Reilly S, Lustig R, Kurtz G, Minturn JE, Shah AC, Waanders AJ, Belasco JB, Cole KA, Fisher MJ, Phillips PC, Balamuth NJ, Storm PB, Hill-Kayser CE. Risk of brainstem necrosis in pediatric patients with central nervous system malignancies after pencil beam scanning proton therapy. Acta Oncol. 2019 Dec;58(12):1752-1756. doi: 10.1080/0284186X.2019.1659996. Epub 2019 Sep 12. PMID: 31512931

2017

Mahdi J, Shah AC, Sato A, Morris SM, McKinstry RC, Listernick R, Packer RJ, Fisher MJ, Gutmann DH. A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. Neurology. 2017 Apr 18;88(16):1584-1589. doi: 10.1212/WNL.0000000000003881. Epub 2017 Mar 22. PMID: 28330960

2016

Shah AC, Minturn JE, Li Y, Belasco JB, Phillips PC, Kang T, Cole KA, Waanders AJ, Pollack R, Didomenico C, Wildes C, Fisher MJ. Carboplatin rechallenge after hypersensitivity reactions in pediatric patients with low-grade glioma. Pediatr Blood Cancer. 2016 Jan;63(1):21-6. doi: 10.1002/pbc.25697. Epub 2015 Jul 31. PMID: 26235452.

Patient experience rating

(based on 42 submissions)
  • Clear Explanation
    4.9 of 5
  • Showed Concern
    4.9 of 5
  • Would recommend
    4.9 of 5
  • Discussion of Proposed Treatment
    4.8 of 5
Learn about the patient experience rating system

About the Patient Experience Rating System

The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question. Responses are measured on a scale of 1 to 5 with 5 being the best score. We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient’s protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments. Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care. The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.